Retinal vascular occlusion after COVID-19 vaccination: analysis of the French pharmacovigilance database

2024-9-1

Elexacaftor/tezacaftor/ivacaftor induced liver enzymes abnormalities in breastfed infants: a series of 3 cases*

2024-9-1

Case report of a slow-metabolism of CYP2D6 which led to a misuse of codeine: how can we detect it and how can we take care?

2024-7-1

A biological pharmacology network to secure the risk of drug-drug interaction with nirmatrelvir/ritonavir

2024-7-1

Effets indésirables de l’association tezacaftor/ivacaftor/elexacaftor pouvant mener à un arrêt de traitement: à propos d’une série de 10 cas

2024-7-1

Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown

2024-7-1

Exposure assessment of titanium dioxide via drugs available on the French market: a nationwide descriptive study

2024-7-1

Impact of new drug releases on heart failure management and hospitalizations in France: a repeated cross-sectional study between 2014 and 2023

2024-7-1

Editorial board

2024-7-1

Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study

2024-7-1

Are clinical data from spontaneous pharmacovigilance reports transmitted via the Ministry of Health's web portal sufficient to generate a signal without further documentation?

2024-7-1

Contents

2024-7-1

Utilisation d’un système d’aide à la décision pharmaceutique dans la valorisation des séjours hospitaliers: évaluation à travers 3 exemples en collaboration avec le département de l’information médicale

2024-7-1

A revisited version of the disputatio for pharmacological training: An educational study

2024-7-1

Pharmacogénétique de l’ototoxicité des aminosides : état des connaissances et des pratiques - recommandations du Réseau francophone de pharmacogénétique (RNPGx)

2024-6-1

Évaluation des dépenses du circuit des produits de santé dans le cadre d’études institutionnelles – Étude de cas au CHU de Toulouse

2024-6-1

COVACPREG, a French prospective cohort study of women vaccinated against Covid-19 during pregnancy

2024-6-1

Concilier régulation du médicament et démocratie sanitaire : rôle des conseillers patient et professionnel de santé à l’ANSM

2024-6-1

Tramadol intoxication in children: an emerging issue

2024-6-1

What is the best source for searching drug with CIP codes in the French health reimbursement data system (SNDS) database?

2024-6-1

Dapagliflozin-induced leukocytoclastic vasculitis

2024-6-1

Neurotoxicity following atezolizumab in a patient with tolerated rechallenge

2024-5-1

Experience and expectations of pharmacogenetic tests in France

2024-5-1

Acute angle closure glaucoma following COVID-19 vaccination

2024-5-1

Contents

2024-5-1

Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS): Interest of skin tests in cross-reactivity to phenobarbital

2024-5-1

Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020

2024-5-1

Could direct oral anticoagulants induce non-hemorrhagic joint disorders?

2024-5-1

Statins and immune-mediated necrotizing myopathy: Variability in the risk

2024-5-1

How could proton pump inhibitors de-prescription be managed in geriatric long-term care?

2024-5-1

Fluoxetine-induced acute pancreatitis: Evidence from a positive re-challenge

2024-5-1

Drug-related hypophosphatemia: Descriptive study and case/non-case analysis of the French national pharmacovigilance database

2024-5-1

Prescription-free consultation: A cross-sectional study in general practice

2024-5-1

Editorial board

2024-5-1

Isotonitazene, a synthetic opioid from an emerging family: the nitazenes

2024-5-1

Un outil d’adaptation individualisée des posologies de médicaments chez le patient adulte obèse

2024-5-1

Predictive factors for acceptance of a long-acting opiate substitution treatment studied through social representations and internalized stigma

2024-5-1

Les dispositifs de soutien à l’innovation et la structuration de l’évaluation médico-économique en France

2024-5-1

Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase

2024-5-1

GPs’ practices when prescribing buprenorphine in primary care: a survey among the Sentinelles network

2024-4-1

Propofol infusion syndrome: Analysis of French pharmacovigilance and World Health Organization Pharmacovigilance (VigiBase®) databases from 2020 to 2023

2024-4-1

Drug-drug interaction and inadequate exposure to voriconazole in critically ill patients with multiple organ failure: a pediatric case study

2024-4-1

Keratodermie aquagénique palmaire secondaire au traitement d’une ostéite chronique par tédizolide : à propos d’un cas

2024-4-1

Profile of adverse drug reactions reported via the Continuum+ platform: results from three-year regional follow-up

2024-4-1

Syndrome de Stevens-Johnson induit par la lymécycline chez un adolescent de 17 ans : cas clinique et revue de la littérature

2024-4-1

Évaluation de la satisfaction des professionnels de santé utilisateurs du site internet du CRAT et lancement d’une nouvelle version

2024-4-1

Discordance between pain specialists and patients on the perception of dependence on pain medication: a multi-centre cross-sectional study

2024-4-1

Hospitalized cocaine detoxification patients in Paris, France: increased patient levels and changing population characteristics since 2011

2024-3-1

Drug-induced glomerular diseases

2024-3-1

Drug-induced fetal and offspring disorders, beyond birth defects

2024-3-1